Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report) shares passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.38. Xtant Medical shares last traded at $0.36, with a volume of 209,214 shares trading hands.
Analyst Ratings Changes
Separately, Craig Hallum set a $1.50 target price on shares of Xtant Medical and gave the company a "buy" rating in a research note on Friday, October 18th.
Get Our Latest Report on XTNT
Xtant Medical Stock Up 0.5 %
The firm has a market cap of $50.04 million, a price-to-earnings ratio of -2.77 and a beta of 0.34. The company has a current ratio of 2.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.42.
Xtant Medical (NYSEAMERICAN:XTNT - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The medical device company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.02). Xtant Medical had a negative return on equity of 37.07% and a negative net margin of 15.45%. The firm had revenue of $27.94 million for the quarter.
Institutional Investors Weigh In On Xtant Medical
An institutional investor recently bought a new position in Xtant Medical stock. Evernest Financial Advisors LLC bought a new stake in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor bought 40,000 shares of the medical device company's stock, valued at approximately $27,000. 69.33% of the stock is currently owned by institutional investors.
About Xtant Medical
(
Get Free Report)
Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
Featured Articles
Before you consider Xtant Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xtant Medical wasn't on the list.
While Xtant Medical currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
